Mercy BioAnalytics

Mercy BioAnalytics has developed the proprietary Mercy Halo™ platform to detect early-stage cancers by analyzing tumor-derived extracellular vesicles in blood. Their lead program, an ovarian cancer screening test, demonstrated high sensitivity (82%) and specificity (98%) in recent studies—significantly outperforming current standards like CA125 and ultrasound. The company’s approach enables low-cost, highly accurate liquid biopsies suitable for broad population screening. Initial focus areas are ovarian and lung cancers; additional programs targeting pancreatic and prostate cancers are suggested by patent activity. The company has raised over $68M to date and recently completed a $41M Series A round led by Novalis LifeSciences with participation from Labcorp, Bruker, Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge Fund, Broadway Angels among others.